近期,加拿大卫生部网站发布信息,警示顺铂的静脉血栓栓塞风险。此项安全性评估是根据国外监管机构发布的处方更新信息开始启动的。顺铂是抗肿瘤药品,与其他疗法联合用于治疗晚期膀胱、睾丸和卵巢癌。于1979年在加拿大上市,仅可通过处方获得。在加拿大市场上共有5种以顺铂为通用名的产品销售,均为1mg/ml规格的静脉注射剂,容量分别为10ml、50ml和100ml。 Recently, Health Canada’s website posted information on the risk of venous thromboembolism with cisplatin. This safety assessment is based on prescription updates issued by foreign regulators. Cisplatin is an anti-cancer drug used in combination with other therapies to treat advanced bladder, testicular and ovarian cancers. It was listed in Canada in 1979 and can only be obtained through prescription. There are 5 products sold under the generic name cisplatin in the Canadian market, each of which is a 1 mg / ml intravenous injection, with capacities of 10 ml, 50 ml and 100 ml, respectively.